Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Lowered by DZ Bank

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by research analysts at DZ Bank from a “strong-buy” rating to a “strong sell” rating in a report issued on Wednesday,Zacks.com reports.

BAYRY has been the topic of a number of other reports. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 20th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $13.28 on Wednesday. Bayer Aktiengesellschaft has a one year low of $5.30 and a one year high of $14.85. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The company has a market cap of $52.19 billion, a price-to-earnings ratio of -147.54, a PEG ratio of 4.77 and a beta of 0.68. The firm has a 50 day simple moving average of $12.13 and a 200 day simple moving average of $9.58.

Trending Headlines about Bayer Aktiengesellschaft

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Bayer says glyphosate supply shortages are not expected outside the U.S., easing concerns about global crop‑protection availability after the U.S. executive order; this reduces near‑term operational disruption risk. Article Title
• Positive Sentiment: The company has proposed a nationwide settlement intended to resolve Roundup litigation, which—if approved and comprehensive—could offer long‑term legal certainty that removes a large overhang on valuation. Article Title
• Neutral Sentiment: Some outlets reported a strong intraday bounce before recent declines; elevated trading volume shows increased investor attention but analyst estimate revisions don’t yet signal a clear upward earnings trend. Article Title
• Negative Sentiment: Bayer’s proposed settlement size and structure prompted skepticism from creditors/analysts and uncertainty over whether it truly closes future claims; some coverage questions whether the deal delivers the finality investors want. Article Title
• Negative Sentiment: Market reaction: shares fell sharply after the Roundup settlement announcement as investors digested the headline cost and legal uncertainty; coverage reports a sizable intraday drop reflecting concern about cash outflow and capital impact. Article Title
• Negative Sentiment: Analyst downgrade: DZ Bank’s rating shift to a much more negative stance amplifies downward pressure by signaling weaker near‑term conviction from sell‑side coverage. Article Title

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.